Trial Profile
Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Lenalidomide (Primary)
- Indications Plasma cell leukaemia
- Focus Adverse reactions
- 17 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to budgetary constraints
- 24 Jul 2018 New trial record